Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in relapsed/refractory B-cell CLL
NCT01982175Phase 2Suspended
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Jul 2011
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Started Jul 2011; status: suspended.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01982175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01982175.